- Stocks
- Healthcare
- NASDAQ: AMGN

Price (delayed)

$220.65

Market cap

$117.9B

P/E Ratio

14.9

Dividend/share

$8.14

EPS

$14.81

Enterprise value

$147.93B

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.

AMGN's quick ratio has surged by 191% year-on-year and by 176% since the previous quarter

Amgen's equity has increased by 46% from the previous quarter

The debt has surged by 67% year-on-year and by 58% since the previous quarter

What are the main financial stats of AMGN

Market
Valuations
Earnings

Shares outstanding

534.33M

Market cap

$117.9B

Enterprise value

$147.93B

Price to book (P/B)

22.03

Price to sales (P/S)

4.5

EV/EBIT

13.74

EV/EBITDA

10.39

EV/Sales

5.65

Revenue

$26.19B

EBIT

$10.77B

EBITDA

$14.24B

Free cash flow

$7.53B

Per share
Balance sheet
Liquidity

EPS

$14.81

Free cash flow per share

$14.1

Book value per share

$10.02

Revenue per share

$49.04

TBVPS

$108.23

Total assets

$88.72B

Total liabilities

$83.37B

Debt

$61.6B

Equity

$5.35B

Working capital

$30.49B

Debt to equity

11.52

Current ratio

3.14

Quick ratio

2.62

Net debt/EBITDA

2.11

Margins
Efficiency
Dividend

EBITDA margin

54.4%

Gross margin

74.9%

Net margin

30.2%

Operating margin

34.3%

Return on assets

11.4%

Return on equity

210%

Return on invested capital

19.4%

Return on capital employed

14.5%

Return on sales

41.1%

Dividend yield

3.69%

DPS

$8.14

Payout ratio

55%

How has the Amgen stock price performed over time

Intraday

0.97%

1 week

-0.3%

1 month

-7.96%

1 year

-14.06%

YTD

-15.99%

QTD

-8.73%

How have Amgen's revenue and profit performed over time

Revenue

$26.19B

Gross profit

$19.63B

Operating income

$8.99B

Net income

$7.92B

Gross margin

74.9%

Net margin

30.2%

The net margin rose by 39% year-on-year and by 21% since the previous quarter

The net income has grown by 38% YoY and by 21% from the previous quarter

The company's operating margin rose by 13% YoY but it fell by 6% QoQ

AMGN's operating income is up by 12% year-on-year but it is down by 6% since the previous quarter

What is Amgen's growth rate over time

What is Amgen stock price valuation

P/E

14.9

P/B

22.03

P/S

4.5

EV/EBIT

13.74

EV/EBITDA

10.39

EV/Sales

5.65

AMGN's EPS is up by 45% year-on-year and by 22% since the previous quarter

The P/E is 33% below the 5-year quarterly average of 22.2 and 22% below the last 4 quarters average of 19.1

Amgen's equity has increased by 46% from the previous quarter

The stock's price to book (P/B) is 41% less than its last 4 quarters average of 37.3 and 10% less than its 5-year quarterly average of 24.5

How efficient is Amgen business performance

The ROE has soared by 121% YoY but it has contracted by 15% from the previous quarter

AMGN's return on sales is up by 40% year-on-year and by 24% since the previous quarter

AMGN's return on assets is up by 23% year-on-year and by 8% since the previous quarter

The ROIC has grown by 13% YoY and by 8% from the previous quarter

What is AMGN's dividend history

DPS

$8.14

Dividend yield

3.69%

Payout ratio

55%

Recent dividends

How did Amgen financials performed over time

Amgen's total assets is 6% more than its total liabilities

AMGN's quick ratio has surged by 191% year-on-year and by 176% since the previous quarter

Amgen's current ratio has soared by 123% from the previous quarter and by 118% YoY

AMGN's debt to equity has shrunk by 71% YoY but it is up by 8% QoQ

The debt has surged by 67% year-on-year and by 58% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.